Relief Therapeutics Holding AG (OTCMKTS: RLFTF) is running higher after the Company up-listed its shares to the OTCQB. The Company which further intends to up-list to a higher exchange such as the NASDAQ or NYSE MKT also raised funds from the Share Subscription Facility bringing the total amount of shares outstanding to 2,534,168,581. To date Relief has raised about $36 million USD which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (Aviptadil) in COVID-19 acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe. Microcapdaily first reported on Relief when the stock first moved off its $0.05 base in early August.
RLFTF has exploded up the charts in recent weeks from a start point of sub $0.05 in July attracting legions of shareholders and emerging as a volume leader in small caps. Aviptadil is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Aviptadil was granted FDA Fast Track Designation and emergency use IND authorization and is showing strong results with a number of covid-19 patients on ventilators returning home in only five days after treatment.
Relief Therapeutics Holding AG (OTCMKTS: RLFTF) operating out of Switzerland is focused on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate Aviptadil, alias vasoactive intestinal peptide, is tested in two phase 2/3 trials on COVID-19 induced ARDS, plus an expanded access program (compassionate use). Aviptadil is a synthetic form of human vasoactive intestinal peptide (VIP) and works by binding to receptors on alveolar cells in the lungs, the same cells that SARS-CoV-2 binds to. Relief says VIP protects these cells and the surrounding pulmonary epithelium by blocking cytokines, preventing cell death and upregulating the production of surfactant, the loss of which is believed to play a role in coronavirus respiratory failure.
Microcapdaily first covered Relief on August 3 when the stock was running up off its $0.05 base reporting at the time: RLFTF is exploding up the charts and emerging as a volume leader after the Company announced RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19.
To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Relief holds orphan drug designations from the FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a U.S. patent (US8178489 formulation for Aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.
In August Relief and its US partner, NeuroRx, Inc. reported aviptadil showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial. Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.2 clinicaltrials.gov NCT04311697.
Chairman of the Board of Directors of Relief, Dr. Raghuram Selvaraju recently stated: “We are proud to meet the enhanced public company requirements to be an OTCQB listed company and thank all share purchasers who are contributing to this fundraising effort. The proceeds from these efforts will enable us to progress the clinical trial of Aviptadil and reach our next milestone on schedule to bring this potentially life-saving drug to patients as fast as possible.”
Tony Searcy updates : pic.twitter.com/jA0cmLrnxE
— andyy2018 (@andyy20181) September 1, 2020
We have a Monster Pick Coming. Subscribe Right Now!
RLFTF is emerging as the hottest stock in small caps as its covid-19 treatment; RLF-100 (Aviptadil) continues to show highly promising results with a number of covid-19 patients on ventilators returning home in only five days after treatment. To date Relief has raised about $36 million USD which will be used primarily to fund the ongoing Fast Track FDA trial of Aviptadil in COVID-19 acute respiratory distress syndrome (NCT04311697) as well as to run a phase 3 study in Europe. Aviptadil is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. In addition to the Emergency Use authorization at Houston Methodist that is now in peer review, there are currently two active trials; a) Phase IIb/III studies in Acute Respiratory Distress Syndrome induced by COVID-19 – 144 patients with an interim review at 102 enrolled patients. Estimated Study Completion Date: September 2020. b) Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19 (AVINALI)- “The Inhaler Trial” Estimated Study Completion Date: October 1, 2020. RLF-100 has been hailed as a possible wunderdrug and has life-saving implications for asthma, pulmonary fibrosis, sarcoidosis, ARDs, MAC / MAI, viral pneumonia and of course coronavirus. Microcapdaily covers Relief on the regular and first reported on the Company on August 3 as Relief was running northbound off its $0.05 base. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.
WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?
Disclosure: we hold no position in Relief either long or short and we have not been compensated for this article.